US Stock MarketDetailed Quotes

KYMR Kymera Therapeutics

Watchlist
  • 40.660
  • +1.520+3.88%
Close Dec 20 16:00 ET
  • 40.900
  • +0.240+0.59%
Post 20:01 ET
2.63BMarket Cap-17.38P/E (TTM)

Kymera Therapeutics Key Stats

EPS
According to the latest financial report of Kymera Therapeutics, the latest earnings per share (TTM) for the company is -0.82. Investing in companies with strong earnings per share can potentially provide higher returns.

Currency: USD

Quarterly

Loading...

FCF
Interested in knowing about Kymera Therapeutics's free cash flow? The latest report shows it as -50.00M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.

Currency: USD

Quarterly

Loading...

Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Kymera Therapeutics shows that the company's current ratio is 8.55, indicating healthy liquidity.

Currency: USD

Quarterly

Loading...

Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Kymera Therapeutics, the quick ratio is 8.29, indicating that the company can meet its short-term debt obligations.

Currency: USD

Quarterly

Loading...

ROE
Want to learn more about the financial health of Kymera Therapeutics? The latest ROE figure is -7.92%, indicating that the company has stable profitability.

Currency: USD

Quarterly

Loading...

ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Kymera Therapeutics, the total asset return on investment (ROA) is -6.72%.

Currency: USD

Quarterly

Loading...

Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Kymera Therapeutics's latest financial report to see how their gross margin is doing - currently at --.

Currency: USD

Quarterly

Loading...

Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Kymera Therapeutics, the net profit margin is -1.67K%, which is a good sign for its profitability.

Currency: USD

Quarterly

Loading...

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.